MarketScreener Editorial Features Altimmune, Inc.
Equities
ALT
US02155H2004
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.765 USD | -1.53% |
|
+13.70% | -6.17% |
| 05-23 | Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025 | |
| 05-19 | Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder | RE |
MarketScreener Editorial Features
Search
 | Central banks to the rescue | March 21, 2023 at 09:59 am |
 | Today on Wall Street: How yesterday’s data could affect Fed policy | June 16, 2021 at 08:37 am |
 | GLOBAL MARKETS LIVE: Alibaba faces heavy fine, good news for Boeing… | March 12, 2021 at 10:14 am |
No results for this search
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- MarketScreener Editorial Features
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition